Ivlv-X1
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 08, 2024
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
(clinicaltrials.gov)
- P1/2 | N=10 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Unknown status ➔ Recruiting | Trial completion date: Dec 2020 ➔ Dec 2027 | Trial primary completion date: Dec 2019 ➔ Dec 2026
Enrollment open • Gene therapy • Trial completion date • Trial primary completion date • Viral vector • Gene Therapies • Genetic Disorders • Immunology • Primary Immunodeficiency
1 to 1
Of
1
Go to page
1